- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Fireweed Metals
Cyclone Metals
Lancaster Resources
Element79 Gold Corp.
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Adeona Pharmaceuticals, Inc., (AMEX:AEN) announced five scientific publications on the role of copper toxicity and zinc deficiency in Alzheimer’s disease and cognitive decline. The author of all these publications is Adeona’s scientific founder and consultant, George J. Brewer, M.D., the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the […]
Adeona Pharmaceuticals, Inc., (AMEX:AEN) announced five scientific publications on the role of copper toxicity and zinc deficiency in Alzheimer’s disease and cognitive decline. The author of all these publications is Adeona’s scientific founder and consultant, George J. Brewer, M.D., the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan.
George J. Brewer, M.D., Adeona’s scientific founder and consultant, remarked, “We are starting to build the peer-reviewed scientific literature that supports the hypothesis that copper toxicity and zinc deficiency is a hallmark of Alzheimer’s disease and cognitive decline. With that scientific infrastructure in place, I believe that high dose oral zinc administration should prove to have a vital therapeutic role in these disease conditions.”
Outlook Reports
Featured Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2344.53 | +0.88 | |
Silver | 27.94 | +0.01 | |
Copper | 4.32 | +0.06 | |
Oil | 85.45 | -0.14 | |
Heating Oil | 2.68 | +0.02 | |
Natural Gas | 1.77 | +0.01 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.